Erythromycin A produced in E. coli for first time: Biosynthetic breakthrough paves way for other pharmaceuticals Date: November 26, 2010 Source: Tufts University Summary: For the first time ...

Erythromycin, a non-peptide motilin receptor agonist, induces phase 3 of the migrating motor complex (MMC) in the antro-duodenum and also reduces oro-cecal transit time. A pediatric study has ...

Because the early results obtained by these workers seemed favorable and encouraging, ¶ and particularly because erythromycin might prove useful in the treatment of staphylococcal infections ...

Erythromycin ophthalmic ointment by Fera Pharmaceuticals Fera Pharmaceuticals announced that erythromycin ophthalmic ointment is now available in a 3.5g package size in addition to the 1g unit ...

Nashville, TN - Use of oral erythromycin is associated with a doubling in the risk of sudden cardiac death, and the use of the antibiotic in combination with drugs that are likely to inhibit its ...

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ...

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection ...